GlaxoSmithKline (NYSE:GSK) – Stock analysts at Jefferies Group issued their Q1 2018 earnings estimates for GlaxoSmithKline in a research report issued on Friday, April 13th. Jefferies Group analyst I. Hilliker forecasts that the pharmaceutical company will post earnings per share of $0.70 for the quarter. Jefferies Group also issued estimates for GlaxoSmithKline’s FY2018 earnings at $2.93 EPS, FY2019 earnings at $3.15 EPS, FY2020 earnings at $3.44 EPS, FY2021 earnings at $3.81 EPS and FY2022 earnings at $4.12 EPS.
GSK has been the subject of several other reports. Zacks Investment Research raised GlaxoSmithKline from a “hold” rating to a “buy” rating and set a $41.00 price objective for the company in a research report on Tuesday, March 6th. Deutsche Bank reissued a “neutral” rating on shares of GlaxoSmithKline in a research report on Monday, April 9th. TheStreet lowered GlaxoSmithKline from a “b-” rating to a “c” rating in a research report on Wednesday, February 7th. JPMorgan Chase reissued a “neutral” rating on shares of GlaxoSmithKline in a research report on Monday, January 29th. Finally, BNP Paribas raised GlaxoSmithKline from a “neutral” rating to an “outperform” rating in a research report on Wednesday, April 4th. One research analyst has rated the stock with a sell rating, ten have assigned a hold rating and five have issued a buy rating to the company. GlaxoSmithKline presently has a consensus rating of “Hold” and an average target price of $40.46.
GSK stock opened at $40.58 on Monday. GlaxoSmithKline has a 1-year low of $34.52 and a 1-year high of $44.53. The company has a debt-to-equity ratio of 4.09, a current ratio of 0.60 and a quick ratio of 0.39. The stock has a market capitalization of $100,714.61, a PE ratio of 14.09, a price-to-earnings-growth ratio of 2.26 and a beta of 0.84.
GlaxoSmithKline (NYSE:GSK) last posted its quarterly earnings data on Wednesday, February 7th. The pharmaceutical company reported $0.72 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.69 by $0.03. GlaxoSmithKline had a return on equity of 130.63% and a net margin of 4.97%. The firm had revenue of $10.14 billion during the quarter, compared to analyst estimates of $9.89 billion.
The company also recently announced a quarterly dividend, which was paid on Thursday, April 12th. Investors of record on Friday, February 23rd were given a $0.633 dividend. This represents a $2.53 dividend on an annualized basis and a yield of 6.24%. This is a positive change from GlaxoSmithKline’s previous quarterly dividend of $0.50. The ex-dividend date was Thursday, February 22nd. GlaxoSmithKline’s payout ratio is presently 89.93%.
Institutional investors have recently modified their holdings of the stock. Field & Main Bank bought a new stake in GlaxoSmithKline in the 4th quarter valued at about $132,000. Amussen Hunsaker Associates LLC bought a new stake in GlaxoSmithKline in the 4th quarter valued at about $141,000. First Dallas Securities Inc. bought a new stake in GlaxoSmithKline in the 4th quarter valued at about $142,000. Belpointe Asset Management LLC bought a new stake in GlaxoSmithKline in the 3rd quarter valued at about $204,000. Finally, California Capital Advisors Inc. bought a new stake in GlaxoSmithKline in the 4th quarter valued at about $210,000. 10.97% of the stock is owned by institutional investors and hedge funds.
COPYRIGHT VIOLATION NOTICE: This news story was first posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this news story on another site, it was illegally stolen and reposted in violation of United States and international copyright laws. The legal version of this news story can be read at https://www.dispatchtribunal.com/2018/04/16/jefferies-group-weighs-in-on-glaxosmithklines-q1-2018-earnings-gsk.html.
GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of vaccines, over-the-counter medicines, and health-related consumer products worldwide. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, dermatology, rare diseases, immuno-inflammation, and HIV, as well as vaccines.
Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.